RxDoctor Payments Data

Abdul Nagaria, MD

Nephrology · Joplin, MONPI 1023025707

Payments from drug & device makers

$1,937in general payments, 2019–2025

Across 32 payments — averaging $60.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$788
  • Otsuka America Pharmaceutical, Inc.$635
  • Amgen$312
  • Baxter Healthcare$70
  • Nxstage Medical, Inc.$61
  • Vifor Pharma, Inc.$21
  • plus $50 from 3 others

What the payments were for

  • Consulting fees$71837%
  • Food & beverage$1,21963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,937 in reported general payments places this provider in the 60th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$236,665
Medicare patients
280
Services billed
1,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate27$98,989
ProsolParenteral Amino Acid 20% No.1110$22,705
Sevelamer Carbonate48$11,313
EliquisApixaban12$7,882
Calcium Acetate80$7,240
ClinolipidFat Emulsion/Olive/Soy/Phospho27$6,788
Clonidine71$6,620
LokelmaSodium Zirconium Cyclosilicate16$5,545
SpsSodium Polystyrene Sulfon/Sorb17$2,583
Terazosin Hcl66$1,583
Amlodipine Besylate186$1,489
Hydralazine Hcl115$1,171
Calcitriol143$1,063
Doxazosin Mesylate53$928
Allopurinol94$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$20$5,54516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 253 nephrology providers in Missouri.

Other nephrology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →